Randomized phase III study of canfosfamide (C, TLK286) plus pegylated liposomal doxorubicin (PLD) versus PLD as second-line therapy in platinum (P) refractory or resistant ovarian cancer (OC)

I. Vergote; N. J. Finkler; J. B. Hall; O. Melnyk; R. P. Edwards; M. Jones; L. Meng; G. L. Brown; E.M. Rankin; J. J. Burke; P. G. Rose

Randomized phase III study of canfosfamide (C, TLK286) plus pegylated liposomal doxorubicin (PLD) versus PLD as second-line therapy in platinum (P) refractory or resistant ovarian cancer (OC)

I. Vergote, N. J. Finkler, J. B. Hall, O. Melnyk, R. P. Edwards, M. Jones, L. Meng, G. L. Brown, E.M. Rankin, J. J. Burke, P. G. Rose

Research output: Contribution to journal › Meeting abstract › peer-review

Original language	English
Article number	5552
Pages (from-to)	-
Number of pages	2
Journal	Journal of Clinical Oncology
Volume	27
Issue number	15 Suppl.
Publication status	Published - 2009
Event	American Society of Clinical Oncology 45th Annual Meeting - Orlando, United States Duration: 29 May 2009 → 2 Jun 2009 http://am.asco.org/

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

http://jco.ascopubs.org/content/by/year/2009

Cite this

Vergote, I., Finkler, N. J., Hall, J. B., Melnyk, O., Edwards, R. P., Jones, M., Meng, L., Brown, G. L., Rankin, E. M., Burke, J. J., & Rose, P. G. (2009). Randomized phase III study of canfosfamide (C, TLK286) plus pegylated liposomal doxorubicin (PLD) versus PLD as second-line therapy in platinum (P) refractory or resistant ovarian cancer (OC). Journal of Clinical Oncology, 27(15 Suppl.), -. Article 5552. http://jco.ascopubs.org/content/by/year/2009

@article{0bc91dc606a2453cb1f6c22c23274203,

title = "Randomized phase III study of canfosfamide (C, TLK286) plus pegylated liposomal doxorubicin (PLD) versus PLD as second-line therapy in platinum (P) refractory or resistant ovarian cancer (OC)",

author = "I. Vergote and Finkler, {N. J.} and Hall, {J. B.} and O. Melnyk and Edwards, {R. P.} and M. Jones and L. Meng and Brown, {G. L.} and E.M. Rankin and Burke, {J. J.} and Rose, {P. G.}",

year = "2009",

language = "English",

volume = "27",

pages = "--",

journal = "Journal of Clinical Oncology",

issn = "0732-183X",

publisher = "American Society of Clinical Oncology",

number = "15 Suppl.",

note = "American Society of Clinical Oncology 45th Annual Meeting, ASCO ; Conference date: 29-05-2009 Through 02-06-2009",

url = "http://am.asco.org/",

}

Vergote, I, Finkler, NJ, Hall, JB, Melnyk, O, Edwards, RP, Jones, M, Meng, L, Brown, GL, Rankin, EM, Burke, JJ & Rose, PG 2009, 'Randomized phase III study of canfosfamide (C, TLK286) plus pegylated liposomal doxorubicin (PLD) versus PLD as second-line therapy in platinum (P) refractory or resistant ovarian cancer (OC)', Journal of Clinical Oncology, vol. 27, no. 15 Suppl., 5552, pp. -. <http://jco.ascopubs.org/content/by/year/2009>

Randomized phase III study of canfosfamide (C, TLK286) plus pegylated liposomal doxorubicin (PLD) versus PLD as second-line therapy in platinum (P) refractory or resistant ovarian cancer (OC). / Vergote, I.; Finkler, N. J.; Hall, J. B. et al.
In: Journal of Clinical Oncology, Vol. 27, No. 15 Suppl., 5552, 2009, p. -.

Research output: Contribution to journal › Meeting abstract › peer-review

TY - JOUR

T1 - Randomized phase III study of canfosfamide (C, TLK286) plus pegylated liposomal doxorubicin (PLD) versus PLD as second-line therapy in platinum (P) refractory or resistant ovarian cancer (OC)

AU - Vergote, I.

AU - Finkler, N. J.

AU - Hall, J. B.

AU - Melnyk, O.

AU - Edwards, R. P.

AU - Jones, M.

AU - Meng, L.

AU - Brown, G. L.

AU - Rankin, E.M.

AU - Burke, J. J.

AU - Rose, P. G.

PY - 2009

Y1 - 2009

M3 - Meeting abstract

SN - 0732-183X

VL - 27

SP - -

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

IS - 15 Suppl.

M1 - 5552

T2 - American Society of Clinical Oncology 45th Annual Meeting

Y2 - 29 May 2009 through 2 June 2009

ER -